Inactive Instrument

NuGenerex Immuno-Oncology, Inc.

NUGX

US67053X1028

Biotechnology & Medical Research

Antigen Express, Inc. Appoints Gabriel N. Hortobagyi as Scientific Advisory Board

May 09, 2012 at 09:30 am

Antigen Express, Inc. appointed Dr. Gabriel N. Hortobagyi, M.D., F.A.C.P. as Scientific Advisory Board.

Latest news about NuGenerex Immuno-Oncology, Inc.

Nugenerex Immuno-Oncology, Inc. Reports Earnings Results for the Third Quarter Ended April 30, 2021	21-06-14	CI
NuGenerex Immuno-Oncology, Inc. has completed an IPO in the amount of $50.000004 million.	21-05-19	CI
NuGenerex Immuno-Oncology, Inc. Submits Protocol, Data, and Manufacturing Information to FDA in Advance of the IND Submission	21-04-12	CI
Nugenerex Immuno-Oncology, Inc. Reports Earnings Results for the Second Quarter Ended January 31, 2021	21-03-12	CI
Nugenerex Immuno-Oncology, Inc. and Generex Biotechnology Corporation Signs an Extension for the Receipt of the USD 5,000,000.00 Upfront Licensing Fee Payment	20-12-17	CI
NuGenerex to Seek Merger or Acquisition Opportunities	20-12-15	CI
Generex Biotechnology Corporation and Nugenerex Immuno-Oncology Grants Licensing Rights to Bintai Healthcare Sdn Bhd	20-11-25	CI
Generex Biotechnology Corporation and NuGenerex Immuno-Oncology Ii-Key-SARS-CoV-2 Vaccine Partner Bintai Kinden Executes its Exclusive Distribution & Licensing Option for Australia and New Zealand	20-11-23	CI
Generex Biotechnology Corporation and NuGenerex Immuno-Oncology, Inc. Sign Distribution and Licensing Agreement with Bintai Healthcare SDN BHD	20-10-09	CI
NuGenerex Immuno-Oncology Announces Closing of a Licensing & Distribution Agreement with Bintai Kinden to Advance the Clinical Development & Commercialization of Ii-Key-SARS-CoV-2 Coronavirus Vaccine for Global Markets	20-10-07	CI
Bintai Healthcare Sdn Bhd Enters into A Distribution and Licensing Agreement with Generex Biotechnology Corporation and Its Majority Owned Subsidiary, Nugenerex Immuno-Oncology, Inc	20-10-06	CI
Generex Biotechnology Corporation and NuGenerex Immuno-Oncology, Inc. Sign Agreement with Bintai Kinden Corporation of Malaysia for the Development and Commercialization of the II-Key-SARS-CoV-2 Coronavirus Vaccine	20-09-24	CI
NuGenerex Immuno-Oncology, Inc. has filed an IPO in the amount of $1 million.	20-09-14	CI
Bintai Kinden Corporation Berhad Announces Memorandum of Understanding with Nugenerex Immuno-Oncology on New Business Opportunity (COVID-19 Vaccine)	20-08-17	CI
Nugenerex Immuno-Oncology Closes $50 Million Financing Facility	20-07-15	CI
NuGenerex Immuno-Oncology Announces Plans to Address the New Emerging Pandemic Threat from G4 EA H1N1 Swine Influenza Virus Using Ii-Key-H1 Peptide Vaccine	20-07-02	CI
NuGenerex Immuno-Oncology Announces Board of Directors	20-07-01	CI
NuGenerex Immuno-Oncology Seeks Acquisition and Investment Opportunities	20-06-17	CI
NuGenerex Immuno-Oncology Advances COVID-19 Vaccine Program with the Manufacturing of Patent-Pending Ii-Key-SARS-CoV-2 Peptides	20-05-22	CI
NuGenerex Immuno-Oncology Announces Publication of Positive Results of the AE37 Phase IIb Breast Cancer Trial	20-04-28	CI
NuGenerex Immuno-Oncology Appoints Independent Director S. Gail Eckhardt, Md to Board of Directors	20-03-02	CI
Generex Biotechnology Subsidiaries Nugenerex Immuno-Oncology and Nugenerex Diagnostics Working to Address the Coronavirus Pandemic and Emerging Risk of Avian Flu Using Ii-Key Peptide Vaccines	20-02-06	CI
NuGenerex Immuno-Oncology Announces Board Changes	20-02-05	CI
Nugenerex Immuno-Oncology Announces Board Changes	20-01-30	CI
NuGenerex Immuno-Oncology Appoints Marvin S. Hausman to Board of Directors	19-12-11	CI

Chart NuGenerex Immuno-Oncology, Inc.

Duration

Period

More charts

NuGenerex Immuno-Oncology, Inc. is a biotechnology company. The Company is focused on the modulation of the immune system and activation of T cells to treat cancer. It is engaged in developing immunotherapeutic products and vaccines based on its patented platform technology, Ii-Key. The Ii-Key is a peptide derived from the major histocompatibility complex (MHC) Class II associated invariant chain (Ii) that regulates the formation, trafficking, and antigen-presenting functions of MHC class II complexes, essential for the activation of T cells in the immune response. The Company's lead immunotherapy product candidate is AE37, an Ii-Key-HER2 peptide vaccine for breast, prostate, and bladder cancer. AE37, an Ii-Key-HER2 vaccine that contains the HER2/neu antigenic peptide linked to the Ii-Key to enhance immune stimulation against HER2, which is expressed in numerous cancers.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+15.82%	122B
REGENERON PHARMACEUTICALS, INC.	+20.35%	114B
ARGENX SE	+17.90%	25.71B
BIONTECH SE	-25.31%	19.02B
GENMAB A/S	-19.51%	15.83B
BEIGENE, LTD.	-19.67%	15.32B
WUXI APPTEC CO., LTD.	-46.87%	14.88B
SAREPTA THERAPEUTICS, INC.	+62.55%	14.82B
NEUROCRINE BIOSCIENCES, INC.	+6.34%	14.1B

Bio Therapeutic Drugs

NuGenerex Immuno-Oncology, Inc.

Equities

NUGX

US67053X1028

Biotechnology & Medical Research

Antigen Express, Inc. Appoints Gabriel N. Hortobagyi as Scientific Advisory Board

Latest news about NuGenerex Immuno-Oncology, Inc.

Chart NuGenerex Immuno-Oncology, Inc.

Company Profile

Sector Bio Therapeutic Drugs